In the randomized SINDAS study, upfront radiotherapy with moderate doses (25–40 Gy in fractions) administered to all sites of oligometastatic disease in EGFR-positive NSCLC before TKI therapy was shown to improve median OS compared to TKI therapy alone (TKI only: 17.4 months; TKI + radiotherapy: 25.5 months; p < 0.001) [1]. Here, EGFR is linked to non-small cell lung carcinoma.